Literature DB >> 24114285

Prevalence and related factors of the absence of anemia among Chinese chronic hemodialysis patients: a multicenter cross-sectional study.

Qijun Wan1, Yongcheng He, Wanfan Zhang, Qiang Wu, Zibo Xiong.   

Abstract

BACKGROUND: Some chronic hemodialysis (HD) patients can maintain normal hemoglobin levels without requiring erythropoiesis-stimulating agents (ESAs). However, the prevalence and the factors associated with this condition in Chinese chronic HD patients have not been reported. The aim of this study was to investigate clinical features, iron metabolism, and other characteristics to survey the prevalence rate and the related factors of this condition among Chinese chronic HD patients.
METHODS: A total of 1,318 chronic HD patients participated in this study. The patients were classified into a non-ESA group (n = 11) and an ESA group (n = 1,307). The r-HuEPO-independent (non-ESA) HD patients were defined as having hemoglobin greater than 12 g/dl for more than 6 months without r-HuEPO injection, blood transfusion, or androgen therapy. Epidemiological and laboratory data were collected. Renal sonography was also performed on each patient to evaluate the formation of renal and liver cysts, and the number and size of the cysts were recorded.
RESULTS: Approximately 0.84 % of all HD patients were found to be r-HuEPO independent. The non-ESA group had a higher proportion of men (79.6 vs. 58.3 %), a longer duration of renal replacement therapy (RRT) (8.6 ± 6.1 vs. 5.1 ± 3.3 years), a higher prevalence of adult polycystic kidney disease (APKD) (46.3 vs. 9.7 %), a higher prevalence of hepatitis C virus (HCV) liver disease (26.2 vs. 3.2 %, P < 0.01), and had older patients (63.3 ± 13.6 vs. 49.6 ± 13.5 years). Endogenous erythropoietin levels in the non-ESA group were significantly higher than those in the ESA group (61.8 ± 27.1 vs. 29.3 ± 11.7 mU/ml). Non-ESA patients had a significantly higher number of renal (38.1 vs. 13.2 %) and hepatic cysts (9.3 vs. 1.9 %), which were also larger in size (2.9 ± 1.6 vs. 1.3 ± 0.3 cm) compared with those of patients in the ESA group. No significant difference in iron metabolism was found between two groups. In the multivariate Cox analysis, the independent predictor factors for the absence of anemia in these HD patients were the number of renal cysts >6 cysts (95 % CI 1.058-1.405; P = 0.00), endogenous erythropoietin levels (95 % CI 1.139-1.361; P = 0.05), HCV+ liver disease (95 % CI 1.129-1.316; P = 0.01), and time on RRT (95 % CI 1.019-1.263; P = 0.05).
CONCLUSIONS: To our knowledge, this study is the first to report on r-HuEPO independence among Chinese HD patients. The prevalence among Chinese chronic HD patients is significantly lower than that reported in the literature. Factors contributing to this condition are complex and multiple. The frequency of this condition is higher in men and in older patients with long-term RRT, in patients with HCV+ liver disease, and in APKD patients. This condition is associated with increased endogenous erythropoietin production and the presence of renal and hepatic cysts.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24114285     DOI: 10.1007/s11255-013-0581-1

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  18 in total

1.  Polycythemia associated with bilateral unilocular renal cysts.

Authors:  N N COHEN
Journal:  Arch Intern Med       Date:  1960-02

2.  Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients.

Authors:  David A Goodkin; Douglas S Fuller; Bruce M Robinson; Christian Combe; Richard Fluck; David Mendelssohn; Tadao Akizawa; Ronald L Pisoni; Friedrich K Port
Journal:  J Am Soc Nephrol       Date:  2010-12-16       Impact factor: 10.121

3.  Erythrocytosis induced by danazol in an anephric patient.

Authors:  I K Barton; M A Mansell
Journal:  Br Med J (Clin Res Ed)       Date:  1987-03-07

4.  Factors related to the absence of anemia in hemodialysis patients.

Authors:  Ursula Verdalles; Soraya Abad; Almudena Vega; Caridad Ruiz Caro; Jara Ampuero; Rosa Jofre; Juan Manuel Lopez-Gomez
Journal:  Blood Purif       Date:  2011-02-24       Impact factor: 2.614

5.  Uremia and the liver. I. The liver and erythropoiesis in chronic renal failure.

Authors:  A Meyrier; P Simon; G Boffa; P Brissot
Journal:  Nephron       Date:  1981       Impact factor: 2.847

6.  The Dialysis Outcomes and Practice Patterns Study (DOPPS): design, data elements, and methodology.

Authors:  Ronald L Pisoni; Brenda W Gillespie; David M Dickinson; Kenneth Chen; Michael H Kutner; Robert A Wolfe
Journal:  Am J Kidney Dis       Date:  2004-11       Impact factor: 8.860

7.  Effect of hepatitis C infection on anemia in hemodialysis patients.

Authors:  Anand Khurana; Allan E Nickel; Mohanram Narayanan; Charles J Foulks
Journal:  Hemodial Int       Date:  2008-01       Impact factor: 1.812

8.  Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality.

Authors:  Juan M López-Gómez; José M Portolés; Pedro Aljama
Journal:  Kidney Int Suppl       Date:  2008-12       Impact factor: 10.545

9.  Factors contributing to higher hematocrit levels in hemodialysis patients not receiving recombinant human erythropoietin.

Authors:  Atsushi Takeda; Takayuki Toda; Shinsuke Shinohara; Yoshiyuki Mogi; Noriaki Matsui
Journal:  Am J Kidney Dis       Date:  2002-07       Impact factor: 8.860

10.  Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Authors:  Ronald L Pisoni; Jennifer L Bragg-Gresham; Eric W Young; Tadao Akizawa; Yasushi Asano; Francesco Locatelli; Juergen Bommer; Jose Miguel Cruz; Peter G Kerr; David C Mendelssohn; Philip J Held; Friedrich K Port
Journal:  Am J Kidney Dis       Date:  2004-07       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.